Tech Company Financing Transactions
Altheus Therapeutics Funding Round
On 3/31/2014, Altheus Therapeutics secured $2 million in funding from Oklahoma Equity Partners and Prolog Ventures.
Transaction Overview
Company Name
Announced On
3/31/2014
Transaction Type
Venture Equity
Amount
$2,035,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
755 Research Pkwy. 435
Oklahoma City, OK 73104
USA
Oklahoma City, OK 73104
USA
Phone
Website
Email Address
Overview
Altheus Therapeutics is developing Zoenasa for the treatment of ulcerative colitis (UC) a form of inflammatory bowel disease (IBD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dennis Schafer
Chief Medical Officer
Richard Harty
Chief Operating Officer
Dayton Reardan
VP - Bus. Development
Justin Briggs
VP - Product Management
Dennis Hair
Browse more venture capital transactions:
Prev: 3/31/2014: 3-V Biosciences venture capital transaction
Next: 3/31/2014: uTest venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs